Efficacy, Safety, and Impact of Combined Extended-Release Tramadol Hydrochloride and Acetaminophen on Inflammatory Mediators in Malignant Lymphoma-Associated Pain
Annals of Pharmacotherapy · 29.10.2026
DOI: 10.1177/10600280261496561 ↗Kurz gefasst
Fachartikel in der Zeitschrift Annals of Pharmacotherapy, online erschienen am 29.10.2026. Verfasst von Xiaohua Qi und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Hematology, The First Affiliated Hospital of Air Force Military Medical University, Xi'an, China. Die Arbeit nennt 38 Literaturangaben.
Abstract (Originalsprache)
Background
Malignant lymphoma-associated pain significantly impairs quality of life and is linked to systemic inflammatory responses. This study evaluated the efficacy and safety of combining extended-release tramadol hydrochloride with acetaminophen compared with monotherapy.
Objective
This study aimed to evaluate the efficacy and safety of tramadol hydrochloride extended-release tablets in combination with acetaminophen versus monotherapy with either agent in the treatment of malignant lymphoma-related pain, and to investigate the effects of these treatment regimens on peripheral pain mediators and systemic inflammatory cytokines.
Methods
A comparative study was conducted involving 165 patients with malignant lymphoma-associated pain (January 2024-December 2025). Patients were assigned to 3 groups: acetaminophen (n = 53), tramadol (n = 55), or combination therapy (n = 57), receiving 28 days of treatment. Primary outcomes included Numerical Rating Scale (NRS) pain scores and analgesic efficacy. Secondary outcomes included peripheral blood pain mediators (substance P [SP], prostaglandin E2 [PGE2], endothelin-1 [ET-1], 5-hydroxytryptamine [5-HT]), inflammatory cytokines (interleukin [IL]-2, IL-4, IL-6, IL-10, tumor necrosis factor- α [TNF- α ] ] , interferon- γ [IFN- γγ ]), and quality of life.
Results
The combination group demonstrated significantly greater reductions in NRS scores and superior analgesic efficacy (91.23%) compared with acetaminophen (71.70%) and tramadol (78.18%) groups ( P < 0 . 05 ) . Combination therapy resulted in the greatest reduction of pain mediators (SP, PGE2, ET-1, 5-HT) and significant modulation of cytokines (lower IL-2, IL-6, TNF- α , IFN- γγ ; higher IL-4, IL-10) ( P < 0 . 05 ) . Quality of life improved significantly more in the combination group ( P < 0 . 05 ) . Adverse event incidence was comparable across groups (18.87%-22.81%; P > 0 . 05 ) , indicating favorable clinical safety. Conclusion and Relevance: The combination of tramadol hydrochloride extended-release tablets and acetaminophen provides superior analgesic efficacy and greater improvement in quality of life compared with either monotherapy in the treatment of malignant lymphoma-related pain, and its mechanism is associated with the synergistic downregulation of peripheral pain mediators and modulation of the inflammatory cytokine profile. During the treatment period, the combination regimen did not significantly increase the risk of adverse reactions, demonstrating a favorable benefit-risk ratio. This report is the first to simultaneously confirm, in this patient population, both the clinical efficacy of this combination regimen and its modulatory effects on the systemic pain-inflammation network, thereby providing a strategy for enhanced analgesia in clinical practice. Based on the data from this study, this regimen may serve as an effective option for the short-term management of moderate to severe pain in patients with malignant lymphoma; however, its long-term efficacy and broad applicability require further investigation.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Hematology, The First Affiliated Hospital of Air Force Military Medical University, Xi'an, China.
- Department of Nursing, The First Affiliated Hospital of Air Force Military Medical University, Xi'an, China.
- Department of Hematology, Xi'an No.3 Hospital, China.
ORCID-Profile: Yan Li
Zitieren
APA
Qi, X., Zhu, L., Li, J., & Li, Y. (2026). Efficacy, Safety, and Impact of Combined Extended-Release Tramadol Hydrochloride and Acetaminophen on Inflammatory Mediators in Malignant Lymphoma-Associated Pain. Annals of Pharmacotherapy. https://doi.org/10.1177/10600280261496561
Vancouver
Qi X, Zhu L, Li J, Li Y. Efficacy, Safety, and Impact of Combined Extended-Release Tramadol Hydrochloride and Acetaminophen on Inflammatory Mediators in Malignant Lymphoma-Associated Pain. Annals of Pharmacotherapy. 2026. doi:10.1177/10600280261496561
BibTeX
@article{Qi2026,
author = {Qi, Xiaohua and Zhu, Li and Li, Jianzhen and Li, Yan},
title = {Efficacy, Safety, and Impact of Combined Extended-Release Tramadol Hydrochloride and Acetaminophen on Inflammatory Mediators in Malignant Lymphoma-Associated Pain},
journal = {Annals of Pharmacotherapy},
year = {2026},
doi = {10.1177/10600280261496561}
}
EUVIMED